The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study.
 
Hiroshi Nokihara
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Toyoaki Hida
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Clovis Oncology; Lilly; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Masashi Kondo
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; pfizer
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly; Novartis; Pfizer
 
Young Hak Kim
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer
Research Funding - Chugai Pharma (Inst)
 
Koichi Azuma
No Relationships to Disclose
 
Takashi Seto
Honoraria - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Fuji Pharma; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Mochida Pharmaceutical Co. Ltd.; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Roche Molecular Diagnostics; Sanofi; Showa Yakuhin Kako; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Verastem (Inst); Yakult Pharmaceutical (Inst)
 
Yuichi Takiguchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Merck Serono; Mitsubishi Tanabe Pharma; Mochida Pharmaceutical Co. Ltd.; Nippon Kayaku; Pfizer; Taiho Pharmaceutical; Titan Medical
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Makoto Nishio
No Relationships to Disclose
 
Hiroshige Yoshioka
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Pfizer
 
Fumio Imamura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Katsuyuki Hotta
Honoraria - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kaken Pharmaceutical; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); MSD (Inst)
 
Satoshi Watanabe
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Ono Pharmaceutical; Pfizer
 
Koichi Goto
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Taiho Pharmaceutical
Research Funding - Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Eisai; GlaxoSmithKline; Kyowa Hakko Kirin; Lilly; MSD; Novartis; Ono Pharmaceutical; OxOnc; Pfizer; Riken Genesis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
 
Kazuhiko Nakagawa
Honoraria - Astellas Pharma; Chugai Pharma; Pfizer
Research Funding - Chugai Pharma (Inst); Novartis (Inst); Pfizer (Inst)
 
Tetsuya Mitsudomi
Honoraria - Chugai Pharma; Pfizer
Consulting or Advisory Role - Chugai Pharma; Novartis; Pfizer; Ventana Medical Systems
Research Funding - Chugai Pharma (Inst); Pfizer (Inst)
 
Nobuyuki Yamamoto
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Nippon Boehringer Ingelheim (Inst)
 
Hiroshi Kuriki
Employment - Chugai Pharma
Stock and Other Ownership Interests - Chugai Pharma
 
Ryoichi Asabe
Employment - Chugai Pharma
 
Tomohiro Tanaka
Honoraria - AstraZeneca; Chugai Pharma; Lilly; ONO Pharmaceutical; ONO Pharmaceutical; Pfizer,Bristol-Myers Squibb; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Tomohide Tamura
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Eisai; Lilly Japan; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha